MedRhythms Launches Clinical Trial of Stroke Asset on Walking Outcomes
MedRhythms, a digital therapeutics company building direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury, announces the launch of a clinical trial that will study MR-010, MedRhythms’ acute stroke asset.
The trial, conducted in partnership with and funded by UMass Memorial Healthcare, will examine the impact of MR-010 on acute stroke walking outcomes.
Led by Dr. Brian Silver, Interim Chair in the UMass Department of Neurology, the trial will assess the feasibility of MR-010 to address walking impairments in those in the acute phase of stroke. It will consist of two phases: the first phase will look at the impact of MR-010 within the acute hospital setting, and the second phase will look at the continued impact of the therapeutic post-discharge, MedRhythms notes in a media release.
MedRhythms Initiates Clinical Trial and Expands Pipeline into Acute Stroke
News provided by
Share this article
Share this article
PORTLAND, Maine, April 28, 2021 /PRNewswire/ MedRhythms, a digital therapeutics company building direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury, today announced the launch of a clinical trial that will study MR-010, MedRhythms acute stroke asset. The trial will be in partnership with UMass Memorial Healthcare and will examine the impact of MR-010 on acute stroke walking outcomes.
Stroke is the world s top cause of long-term disability due to the high prevalence of stroke across the globe as well as its devastating health impacts. Over a third of stroke survivors live in the United States and, according to the CDC, approximately 800,000 people in the US suffer a stroke annually.
MedRhythms, a Portland-based digital health startup that uses sensors, software and music to help restore function lost to neurologic disease or injury, on Wednesday announced the launch of a clinical trial related to acute stroke.
The trial will be in partnership with UMass Memorial Healthcare and will examine the effect of a solution developed by the company on walking by patients with acute stroke.
Wednesday s announcement comes as MedRhythms prepares to launch a trial in collaboration with Boston University related to Parkinson s disease in the next few weeks, and amid an ongoing pivotal trial related to chronic stroke that has been expanded to eight trial sites.
DARTMOUTH Nursing students at the University of Massachusetts Dartmouth may have missed out on a conventional curriculum this year, but what they gained in experience is invaluable.
Mark W. Gregg, a junior at UMD, has helped out at testing sites and vaccination clinics around the SouthCoast as part of his community health class, administering over 150 vaccines at the VF Outlet in Dartmouth and the Liberal Club in Fall River. For his clinical, he helped out at a local site for eight hours every Tuesday, resulting in an average total of 70 hours for the semester. While we missed out on some opportunities, we were blessed with the other side, Gregg said.
State DPH identifies services Baystate Health must address before closing Mary Lane Outpatient Center in Ware
Updated 12:26 PM;
The Springfield-based provider has been asked to respond in early May.
Baystate Health plans to close the emergency department by June and shutter the facility completely within two years.
In an April 16 letter to Baystate Health, the state DPH says they have 15 days from receipt of the notification to respond. The department oversees requests when a provider wants to close a hospital or eliminate essential services,
“The plan the Hospital submits to the Department will be reviewed to determine if it appropriately assures access to the essential services in question following the plans to close the Satellite Emergency Facility and discontinue other hospital-based services at Baystate Mary Lane Outpatient Center,” the state DPH wrote.